Palatin Technologies (PTN) Registration Filing summary

Company overview and business model

• Focuses on developing first-in-class medicines targeting melanocortin receptor systems for diseases with unmet medical need and commercial potential.

• Pipeline includes obesity, ocular, and gastrointestinal indications, with lead programs in obesity (GLP-1 adjunct therapy), dry eye disease, and ulcerative colitis.

• Vyleesi, an FDA-approved melanocortin receptor agonist for HSDD, was sold to Cosette in December 2023, with potential milestone payments.

• Business strategy emphasizes internal development, strategic alliances, and funding through asset sales and licensing.

Financial performance and metrics

• Reported a net loss of $29.7 million for the year ended June 30, 2024, with an accumulated deficit of $452.0 million as of December 31, 2024.

• Cash, cash equivalents, and marketable securities totaled $3.4 million as of December 31, 2024, with current liabilities of $9.6 million.

• No anticipated significant milestone payments from Vyleesi for the next 12 to 24 months; future funding dependent on external sources.

• Substantial doubt exists about the ability to continue as a going concern for one year from the last financial statement date.

Use of proceeds and capital allocation

• Net proceeds from the offering are intended primarily for working capital and general corporate purposes, including development of obesity and melanocortin-4 agonist programs.

• Estimated net proceeds of $11.5 million if the maximum number of securities is sold, with lower amounts possible due to the best-efforts structure.

• Management retains broad discretion over the use of proceeds, with no specific acquisitions planned.